What Is Vesugen?
Vesugen, sometimes transliterated Vezugen, is an experimental three-amino-acid peptide usually identified as lysine-glutamic acid-aspartic acid, abbreviated KED. It belongs to the Russian short-peptide bioregulator programme and is associated with blood vessels and the vascular endothelium.
Published research includes cultured endothelial cells, computational gene-binding work, models of low oxygen, a mouse model of Alzheimer's disease and several small human reports. Two uncontrolled studies followed 41 patients with vascular disease, while another involved 32 people with multiple chronic conditions and organic brain syndrome.
These papers report changes in blood-flow measurements and laboratory markers, but do not provide the randomisation, masking, comparison groups, prespecified outcomes or safety reporting expected of a reliable treatment trial. Vesugen is not an approved vascular medicine.
What is Vesugen made from?
The reported sequence is:
`Lys-Glu-Asp (KED)`
These names refer to lysine, glutamic acid and aspartic acid. A tripeptide contains three amino-acid residues connected by two peptide bonds. Lysine is generally positively charged under biological conditions, while glutamic acid and aspartic acid are generally negatively charged.
Vesugen must not be confused with Vesilut or Vesilute. Vesilut is commonly described as the ED dipeptide and marketed with bladder-related claims. The similar names do not make the compounds interchangeable.
What does vascular bioregulator mean?
The vascular endothelium is the single-cell lining inside blood vessels. It helps regulate vessel tone, clotting, inflammation, permeability and the movement of cells and nutrients between blood and tissue.
The short-peptide programme proposes that KED supports gene regulation in endothelial and other vascular cells. Calling it a vascular bioregulator describes that research framework, not an established clinical function.
Vessels differ greatly across the body. Large arteries, tiny capillaries and veins have different structures and roles. Evidence from one cultured cell type or one limb artery cannot establish protection across the entire cardiovascular system.
What did the endothelial-cell ageing study find?
A 2014 paper studied Vesugen and another peptide called D-7 in tissue cultures from young and old animals and in separated vascular endothelial cells. The researchers measured Ki-67, a protein associated with cells moving through the division cycle.
Ki-67 expression had fallen in older cultures. Vesugen and D-7 increased the marker under the reported conditions. The authors also used molecular docking to model peptide interaction with the promoter of MKI67, the gene encoding Ki-67.
A promoter is a regulatory region near a gene where molecular machinery assembles to begin transcription. Docking predicts a possible physical arrangement but does not show direct binding in a living cell.
Increasing Ki-67 suggests more cells entered the division cycle. It does not prove healthier vessels. Controlled endothelial repair can help after injury, but excessive or misplaced proliferation can contribute to abnormal vessel growth or thickening.
Does increased endothelial proliferation mean vascular repair?
Not by itself. Repair requires cells to form an intact, appropriately organised barrier with normal signalling. A rise in a proliferation marker does not show correct alignment, nitric-oxide production, resistance to clotting or long-term vessel function.
In atherosclerosis, the endothelium is damaged, but the vessel wall also contains inflammatory cells, cholesterol deposits, scar tissue and altered smooth muscle. Restenosis, re-narrowing after an artery has been treated, can involve excessive smooth-muscle growth.
A useful experiment must distinguish beneficial endothelial replacement from unwanted proliferation elsewhere. The Ki-67 study did not establish that balance in a living person.
What did the cell-differentiation study report?
A 2012 study examined differentiation markers in ageing cultures of human embryonic pancreatic and bronchial cells and human prostate fibroblasts. Vesugen was tested in the fibroblast system and increased CXCL12 and WEGC1, factors associated with cell signalling and differentiation.
Fibroblasts produce components of the extracellular matrix, the support network surrounding cells. They are not endothelial cells, and the study did not measure blood flow or vessel tone.
The result suggests that KED can change selected protein measurements outside the proposed target tissue. It does not demonstrate vascular specificity or clinical rejuvenation.
What is endothelin-1, and what was reported?
Endothelin-1 is a signalling peptide made by endothelial cells. It is a strong vasoconstrictor, meaning it can narrow blood vessels, and it participates in inflammation and cell growth. Excess endothelin signalling occurs in several cardiovascular diseases.
A 2017 review-level paper describes KED in models of atherosclerosis and restenosis and reports normalisation of endothelin-1 expression. The accessible abstract does not provide the complete primary experimental detail needed to assess every model, concentration and comparison.
Normalising a protein measurement is not the same as reducing plaque, preventing re-narrowing or improving survival. It is a mechanistic clue requiring confirmation through functional experiments and clinical outcomes.
Was Vesugen tested under low-oxygen conditions?
One model paper compared Vilon, Epitalon, Vesugen and Pinealon under hypobaric hypoxia. Hypoxia means inadequate oxygen, while hypobaric conditions simulate the lower air pressure encountered at altitude.
The abstract describes antihypoxic activity for the tested peptides. It does not establish protection from a heart attack, stroke or critical limb ischaemia. These conditions involve interrupted blood flow, inflammation and tissue injury rather than low ambient pressure alone.
The experiment may support further stress-response research, but its clinical relevance is uncertain.
What did the lower-limb arterial study report?
A 2013 Russian-language paper followed 41 patients who had undergone surgery for chronic lower-limb arterial insufficiency. This condition occurs when narrowed or blocked arteries cannot provide enough blood to the legs.
The researchers compared clinical and ultrasound blood-flow measurements before and after a course of Vesugen described as monotherapy. They reported significant improvement in symptoms and objective circulation measurements.
This was a before-and-after report without a stated randomised control group. Patients had also undergone vascular surgery, which makes it difficult to separate natural recovery, the operation, concurrent care and Vesugen. Ultrasound measurements can support assessment but do not replace walking ability, wound healing, amputation and cardiovascular outcomes.
The study generates a hypothesis. It does not establish that Vesugen treats peripheral artery disease.
What did the erectile-dysfunction study report?
A 2014 paper studied 41 patients with vasculogenic erectile dysfunction associated with atherosclerosis. Vasculogenic means the condition was attributed mainly to impaired blood flow.
The authors compared clinical and instrumental measurements before and after Vesugen monotherapy and reported improved blood flow through the main penile artery. The indexed abstract does not describe random allocation, placebo control or masking.
Erectile function depends on arterial inflow, trapping of blood within erectile tissue, nerves, hormones, medicines and psychological factors. A blood-flow measurement is relevant but does not by itself establish reliable erections, sexual satisfaction or sustained benefit.
Without a comparison group, expectation, measurement variability and changes in other risk factors cannot be excluded. The paper is insufficient to place Vesugen alongside established erectile-dysfunction treatments.
Could the two 41-patient papers describe the same cohort?
The papers share several authors, similar language, the same number of patients and closely related vascular topics. One focuses on people after lower-limb arterial surgery, while the other describes vasculogenic erectile dysfunction.
The accessible abstracts do not clearly establish whether these were fully separate groups, overlapping analyses or different outcomes from one programme. They should not automatically be counted as 82 independent participants.
This uncertainty illustrates why transparent recruitment dates, participant flow, baseline characteristics and trial registration matter. Without them, the apparent size of an evidence base can be overstated.
What did the 32-person ageing study find?
A 2015 paper involved 32 people aged 41 to 83 with multiple chronic conditions and organic brain syndrome in remission. Organic brain syndrome is an older, broad term for cognitive or behavioural impairment attributed to brain disease or injury.
Participants received Vesugen or Pinealon within a study of biological-age indicators. The authors reported anabolic and geroprotective findings, with Vesugen appearing stronger on their selected measures. “Biological age” is not one universally accepted clinical endpoint. Its value depends on the exact algorithm and whether it predicts meaningful outcomes.
The same abstract reports pro-oxidant activity measured by chemiluminescence and a decrease in circulating CD34-positive cells interpreted as inhibition of blood-cell formation. CD34 is a marker found on several progenitor cell populations, including blood-forming cells.
Those findings complicate a simple beneficial narrative. A reduction in CD34-positive cells is not evidence of safer ageing, and pro-oxidant activity may signal increased oxidative chemistry. The study was small, heterogeneous and inadequately controlled for a claim about slowing ageing.
Does Vesugen slow human ageing?
No reliable evidence shows that it does. Ageing affects many organs and produces gradual changes in disease risk and functional reserve. A short study using composite biological-age markers cannot show longer life or extended healthy function.
Claims of geroprotection require validated outcomes, transparent algorithms, a control group and long follow-up. Changes in metabolism, cell markers or a calculated age score may not predict falls, disability, cardiovascular events, dementia or mortality.
The 32-person paper also reported potentially adverse laboratory signals. It cannot support a general anti-ageing claim.
Was KED studied in an Alzheimer's mouse model?
A 2021 study tested KED and EDR in 5xFAD mice, a genetically engineered model that develops amyloid-related features of Alzheimer's disease. The paper examined endothelial and neuronal survival, neuroplasticity and dendritic spines, small protrusions through which neurons receive signals.
KED was associated with selected cellular and neural changes. This remains an animal model with forced genetic pathology. Many interventions that affect amyloid-model mice do not improve human dementia.
The experiment does not show that Vesugen prevents cognitive decline, treats Alzheimer's disease or reaches an effective concentration in the human brain. Vascular effects may be relevant to brain health, but relevance is not clinical proof.
Is the proposed gene-regulation mechanism established?
The programme proposes that KED influences gene expression through interaction with regulatory DNA or chromatin. The MKI67 docking result offers a predicted site, while cell experiments report changes in Ki-67 and other proteins.
Docking does not establish direct binding in living human tissue. A change in a downstream protein can arise through many pathways. The KED sequence also produces effects in fibroblasts, neural models and immune-related cells, making simple vascular specificity uncertain.
A complete mechanism would require physical target engagement, sequence controls, concentration-response relationships and experiments showing that disrupting the proposed binding prevents the functional effect.
Could Vesugen increase unwanted vessel growth?
Endothelial proliferation can support healing and formation of new vessels in ischaemic tissue. It can also contribute to abnormal angiogenesis in tumours, eye disease and inflammatory conditions.
The current studies do not show that Vesugen directs proliferation only where it is useful. Long-term research would need to assess abnormal vessels, plaque stability, smooth-muscle growth and tumour biology.
This is an unresolved safety question rather than evidence that the peptide causes cancer. It follows directly from the claimed proliferation mechanism.
Has Vesugen undergone a modern clinical trial?
No large randomised, placebo-controlled, independently replicated trial was identified through October 2026. The human reports are small and provide limited methodological detail.
Randomisation allocates participants by chance to create comparable groups. A placebo helps separate treatment effects from expectation and natural change. Masking keeps participants and assessors unaware of assignment, reducing biased behaviour and measurement.
The Vesugen papers do not provide this level of protection against bias. Their findings should therefore be described as preliminary human observations, not established efficacy.
What would convincing vascular evidence require?
Early studies would confirm identity, pharmacokinetics and tissue exposure. A peripheral artery disease trial would use standard background care and measure walking performance, symptoms, ankle-brachial pressure, wounds, revascularisation, amputation and cardiovascular events.
The ankle-brachial index compares blood pressure at the ankle with pressure in the arm and helps assess arterial narrowing. Ultrasound flow can complement it but should not stand alone.
For erectile dysfunction, validated erectile-function scores and successful intercourse outcomes would be combined with safety monitoring. Cardiovascular risk factors and other treatments would need control. Atherosclerosis prevention would require much larger and longer trials.
None of these evidence programmes has been completed.
What is known about absorption and distribution?
No adequate human pharmacokinetic study has measured intact KED over time. As a tripeptide, it may interact with peptide transporters, but predicted or general transport does not establish the amount reaching blood and vessels.
Peptidases can break KED into smaller fragments and amino acids. An assay must distinguish intact peptide from those metabolites. Human half-life, oral bioavailability, protein binding, organ distribution and clearance remain unknown.
What is known about safety?
The clinical reports do not provide an adequate safety database. A vascular compound should be assessed for blood pressure changes, dizziness, bleeding, clotting, heart rhythm, fluid balance and interactions with antiplatelet, anticoagulant and blood-pressure medicines.
The 32-person study reported pro-oxidant activity and fewer circulating CD34-positive cells. These are not proven clinical harms, but they are signals that require explanation rather than omission.
Potential proliferation outside the intended tissue also needs long-term study. Sparse reports cannot detect uncommon or delayed adverse effects.
Product quality adds uncertainty. A label cannot prove KED sequence, content, sterility or freedom from bacterial endotoxins. Material described as Vesilut rather than Vesugen may even represent a different sequence.
How is Vesugen synthesised and checked?
KED can be assembled through solid-phase peptide synthesis. Protected amino acids are coupled in order while the growing chain remains attached to a resin. Temporary protecting groups limit unintended reactions. The tripeptide is then released, deprotected and purified.
Mass spectrometry can confirm molecular mass, while fragmentation adds sequence information. Chromatography separates KED from deletion sequences, free amino acids and related impurities. Further testing can assess peptide content, counterions, water, residual solvents and stability.
Regulated sterile research would require batch consistency, potency, particles, sterility and endotoxin controls. This is a quality overview, not a production protocol.
How was Vesugen developed?
| Period | Development |
|---|---|
| 1970s onward | Soviet and Russian programmes investigated organ-derived peptide preparations |
| 2000s | KED appeared as a vascular-associated synthetic tripeptide in model research |
| 2008 | In vitro and hypoxia studies reported biological activity of Vesugen among other peptides |
| 2012 to 2014 | Differentiation, endothelial proliferation and two small human vascular reports were published |
| 2015 | A 32-person study reported mixed ageing-related laboratory findings |
| 2017 to 2021 | Atherosclerosis-mechanism and Alzheimer's mouse-model papers extended the preclinical record |
| Through October 2026 | No definitive randomised human trial was identified |
Is Vesugen approved?
No. Vesugen is not approved by the United States Food and Drug Administration, the United Kingdom Medicines and Healthcare products Regulatory Agency or the European Medicines Agency.
How strong is the evidence overall?
| Question | Best available evidence | Defensible conclusion |
|---|---|---|
| Does KED affect endothelial-cell markers? | Cell culture and docking studies | Proliferation-related measurements changed |
| Does Vesugen improve lower-limb blood flow? | Uncontrolled 41-person report after surgery | Improvement was reported, but causation is unresolved |
| Does it improve vasculogenic erectile dysfunction? | Uncontrolled 41-person report | Preliminary and high risk of bias |
| Does it slow ageing? | Small heterogeneous 32-person study | Not established |
| Does it prevent heart attack or stroke? | No outcome trial | Unknown |
| Is it safe in people? | Sparse and inadequate reporting | Unknown |
| Is it approved? | No FDA, MHRA or EMA approval | No |
Frequently asked questions
What is Vesugen?
It is an experimental tripeptide associated with endothelial and vascular research.
What is its sequence?
It is usually reported as Lys-Glu-Asp, abbreviated KED.
Is Vesugen the same as Vesilut?
No. Vesilut is commonly reported as the shorter ED dipeptide and carries different claims.
Does Vesugen improve circulation?
Two small uncontrolled reports described improved blood-flow measurements, but reliable treatment benefit has not been established.
Does it treat erectile dysfunction?
One weak 41-person report exists. It is insufficient to establish effectiveness.
Does Vesugen remove arterial plaque?
No study demonstrates plaque removal.
Does it prevent heart attack or stroke?
No clinical outcome trial has tested those claims.
Does Vesugen slow ageing?
No reliable evidence shows slower human ageing or longer healthy life.
Is Vesugen known to be safe?
No adequate human safety profile exists.
Is Vesugen approved?
It is not approved by the FDA, MHRA or EMA.
Sources
Research reviewed through October 2026.